Interestingly, studies have also revealed antioncogenic roles of STAT3 in RAS-dependent HCC [81] and early-stage HCC developed from carbon tetrachloride (CCl4)-induced liver fibrosis [82], implying that specific genetic context and etiology of the disease may impact the outcome of STAT3-targeted therapeutics. This evidence concerns the gene STAT3 and hepatocellular carcinoma.